ArticleScientific reports2025
COX-2/PGE₂ signaling drives Toxocara canis-induced lung pathology by enhancing plasminogen activator activity and collagen VI degradation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxocara canis infection induces severe pulmonary pathology, including hemorrhage, inflammation, and extracellular matrix (ECM) degradation, though the underlying mechanisms remain unclear. This study explores the role of cyclooxygenase-2 (COX-2) in lung injury during T. canis infection, focusing on its regulation of plasminogen activator (PA) activity and collagen type VI (COL6) degradation. A murine model was established by orogastric inoculation of 2000 embryonated T. canis eggs. Lung tissues were analyzed via histopathology, ELISA, Western blotting, and immunohistochemistry. COX-2 inhibition with celecoxib was used to assess its effects on COX-2/PGE₂ signaling, PA activity, PI3K/AKT pathway activation, and COL6 degradation. Infection significantly upregulated COX-2, peaking at day 7, correlating with increased PA activity and COL6 cleavage (70/50 kDa fragments). Celecoxib suppressed COX-2/PGE₂, downregulated PI3K/AKT, reduced PA activity, and preserved COL6 integrity, mitigating lung injury. Mechanistically, COX-2/PGE₂ enhances PA activation via PI3K/AKT, exacerbating COL6 degradation. In conclusion, COX-2 drives lung pathology in toxocariasis by modulating PA activity and COL6 degradation, suggesting that targeting COX-2/PGE₂ signaling could ameliorate infection-induced pulmonary damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.